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ABSTRACT: The relationship between sex steroids and cancer has been studied
for more than a century. Using an original intact cell analysis, we investigated
sex steroid metabolism in a panel of human cancer cell lines, either hormone
responsive or unresponsive, originating from human breast, endometrium, and
prostate. We found that highly divergent patterns of steroid metabolism exist
and that the catalytic preference (predominantly reductive or oxidative) is
strictly associated with the steroid receptor status of cells. We explored intra-
tissue concentrations and profiles of estrogens in a set of human breast tumors
as compared to normal mammary tissues, also in relation to their estrogen re-
ceptor status. In particular, we showed that, with hydroxyestrogens represent-
ing the majority of all tissue estrogens, concentrations of individual
metabolites, as well as their ratios, significantly differ when comparing normal
tissue with cancer tissues or when they are related to the overall survival of can-
cer patients.
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INTRODUCTION
The relationship between sex steroids and cancer has been studied for more than
a century. In the last decade, there have been a number of milestone achievements,
especially in the study of their mechanism of action, receptors, and interaction with
other signaling systems. Recently, two major issues have emerged: (1) The number
of target tissues and cells identified for gonadal steroids has enormously increased
over the last few years, to such a point that it has become easier to enumerate those
tissues where no evidence has been provided thus far for a direct action of steroids.
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(2) It is now recognized that steroid action goes far beyond the classical receptor-
mediated mechanism. Steroid actions are also based upon rapid, membrane-bound
responses and an intricate network of interaction and crosstalk with different intra-
cellular signaling pathways. On the other hand, the potential role of gonadal steroids,
especially estrogens, in both development and progression of human endocrine-re-
lated tumors remains unresolved. The seeming inconsistency that these tumors have
a higher incidence in aged subjects, just when a steady decline of steroid formation
rates and circulating levels occurs, remains troubling. This apparent contradiction
has been partly unraveled by studies indicating that steroid target tissues (specifical-
ly breast, endometrium, and prostate) are endowed with an assorted repertoire of ste-
roid enzymes and are able to locally produce and accumulate biologically active
steroid metabolites. This may eventually lead to intratissue amounts of steroids 10
to 100 times greater then those found in plasma—even in subjects aged 50 years and
above. In addition, a deeper understanding of the carcinogenesis process indicates
that, depending on the tumor type, 20 to 50 years may be required to complete the
phenotypical and genotypical transformation of a single initiated cell, hence ac-
counting for the higher cancer incidence rates found in older ages.
Our own research group studied the role of sex steroids in hormone-related tu-
mors, notably breast, endometrial, and prostate cancer. In 1977, we first noted that
breast cancer patients have urinary levels of estrogens significantly higher than those
found in healthy postmenopausal women.1 Further study revealed that “unusual” es-
trogen metabolites (more polar derivatives as opposed to classical estrogens) repre-
sent the majority of urinary estrogens in breast cancer patients.2 Subsequently, we
showed that unusual metabolites are excreted in markedly greater amounts in en-
dometrial cancer patients whose tumors are estrogen receptor (ER)–negative.3 Using
an original intact cell analysis,4 we investigated sex steroid metabolism in a panel of
human cancer cell lines, either hormone responsive or unresponsive, originating
from human breast, endometrium, and prostate. We found that highly divergent pat-
terns of steroid metabolism exist and that the catalytic preference (predominantly re-
ductive or oxidative) is strictly associated with the steroid receptor status of cells.5−7
More recently, we have explored intratissue concentrations and profiles of estrogens
in a set of human breast tumors as compared to normal mammary tissues, also in re-
lation to their ER status.8 In particular, we showed that, with hydroxyestrogens rep-
resenting the majority of all tissue estrogens, concentrations of individual
metabolites, as well as their ratios, significantly differ when comparing normal tis-
sue with cancer tissues or when they are related to the overall survival of cancer
patients.
In the following sections, we review data from our own in vivo and in vitro studies
on sex steroid concentrations and metabolism in target tissues and cells, and provide
a better understanding of the potential role of gonadal steroids, especially estrogens,
in both cancer development and progression.
INTRATISSUE ESTROGENS
In a recent report,8 we inspected intratissue amounts and profiles of estrogens in
a set of human breast tumors (20 cases) as compared to normal mammary tissues ob-
tained from healthy women who underwent surgery for reduction mammoplasty
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(6 cases). Although variable concentrations of hydroxylated estrogens were detect-
ed, they consistently accounted for more than 80% of all estrogens. Furthermore,
various hydroxyestrogens showed significantly different amounts when comparing
normal and malignant human breast tissues. Identity and amounts of individual es-
trogen derivatives were also authenticated using gas chromatography/mass spec-
trometry (GC/MS), as reported elsewhere. A typical GC/MS profile of 2OHE1 is
shown in FIGURE 1.
In this study, concentrations of 16αOHE1 were nearly 3.8-fold higher in cancer-
ous tissues than in normal tissues, even though this difference was not significant
(P = 0.07), presumably because of the limited number of cases included in the study
(FIG. 2). Conversely, 2OHE1 levels were almost equivalent in normal and cancer tis-
sues, while its methoxy derivative, 2MeOE1, was found in significantly greater
amounts (P = 0.024) in malignant tissues (FIG. 3). Interestingly, 4OHE1 and 4OHE2
FIGURE 1. Selected ion gas chromatograph of the purified peak fraction from a breast
tumor tissue extract. Ions monitored at m/z 502 (M+) and 487 (M-15)+ for the 2OHE1 es-
trogen derivative. (Reproduced with permission from Castagnetta et al.16)
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levels were strikingly different in normal versus cancer tissues, with the former be-
ing markedly higher and the latter significantly greater in normal and malignant
breast tissues, respectively (FIG. 4). The 4OHE2:4OHE1 ratio was found to be <0.1
in normal and >3 in cancer tissues, suggesting that 4-hydroxylase activity on E2 and
E1 is differentially regulated. As far as 4-methoxy derivatives of both E1 and E2 are
concerned, an equivalent situation occurs, with 4MeOE1 being elevated in normal
and 4MeOE2 in cancer tissues (FIG. 5). It should be emphasized that methoxy deriv-
atives of both estrone (E1) and estradiol (E2) are in far lower amounts than their par-
ent hydroxyestrogens, except for normal cases, where the ratio of 4MeOE2 to
4OHE2 is greater than 1.6. Furthermore, 4OHE2 levels in cancer tissues were around
eight times higher than in normal tissues and sevenfold greater than those of intratu-
mor 16αOHE1. As reported in TABLE 1, the ratio of 2OHE1:16αOHE1 changes dra-
matically in malignant tissues, dropping to 1.5 from 8.3 in normal breast tissues.
This is exclusively the result of the significant rise of 16αOHE1 in cancer cases
(nearly fourfold), since 2OHE1 levels remain almost equivalent in normal and ma-
lignant tissues. Interestingly, ratios of 4-OHE1 to 2-OHE1 and OHE2, as well as
FIGURE 2. Intratissue concentrations of 16αOHE1 in normal and malignant human
breast tissues.
FIGURE 3. Intratissue concentrations of 2OHE1 (A) and 2MeOE1 (B) in normal and
malignant human breast tissues. 
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TABLE 1. Ratio values of hydroxyestrogens in normal and malignant human breast
tissues
NOTE: Values are expressed as mean ± SE.
Breast
tissue
2/16
OHE1
4/2
OHE1
4/2
OHE2
4/4
OHE1/OHE2
Normal (N = 6) 8.32 ±  4.58 44.61 ±  42.25 1.45 ±  0.47 60.91  ±  41.92
Cancer (N = 17) 1.54  ±  0.11 1.56  ±  0.77 13.82  ±  9.78 4.43  ±  1.98
t test P = 0.016 P = 0.087 P = 0.464 P = 0.028
FIGURE 4. Intratissue concentrations of 4OHE1 (A) and 4OHE2 (B) in normal and
malignant human breast tissues. 
FIGURE 5. Intratissue concentrations of 4MeOE1 (A) and 4MeOE2 (B) in normal and
malignant human breast tissues.
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those of 4OHE1 to 4OHE2, reveal a significant difference when comparing normal
with cancerous breast samples (TABLE 1). In particular, values of 4OHE1:2OHE1
and 4OHE2:2OHE2 ratios were markedly greater in normal and in malignant breast
tissues, respectively, implying that 4OHE1 is prevalent in normal tissues, while
4OHE2 is predominant in cancer cases. This eventually led the 4OHE1:4OHE2 ratio
to be significantly (P = 0.028) higher in normal than in cancer tissues (TABLE 1).
Relevant literature on intratissue amounts of estrogens in human breast is some-
what scarce and inconsistent. Our data are in agreement with those of Cavalieri and
colleagues,9 although in our work concentrations of both classical (E2, E1, E3) and
hydroxy estrogens are found to be markedly greater (10 to 50 times) than those re-
ported in Cavalieri’s paper. This seeming inconsistency may be explained on the ba-
sis of the different methodological approaches used for estrogen extraction and
chromatography, our recovery values being generally high (65–95%) and frequency
of detection for classical and hydroxylated estrogens being generally higher with re-
spect to that obtained by Cavalieri and colleagues (our study: normal breast, 34–
67%; malignant breast, 65–98%. Cavalieri’s study: normal breast, 10–43%; malig-
nant breast, 18–57%).
IN VITRO STUDIES
There is concurrent evidence in the literature that distinct metabolic patterns of ei-
ther estrogen or androgen are encountered in cultured human cancer cell lines derived
from the main endocrine-related tumors (such as breast, endometrium, and prostate),
depending on their steroid receptor status and response to hormones.5−7, 10,11 This
different metabolic aptitude mostly relates to the activity of the 17β−hydroxysteroid
dehydrogenase (17βHSD) enzyme system and is reflected in the prevalence of reduc-
tive metabolism in the receptor-positive, hormone-responsive cells; while oxidative
pathways are largely dominant in receptor-negative, unresponsive cells. This figure is
further refined by the evidence that, in addition to 17βHSD, different steroid enzyme
activities, such as sulfotransferase/sulfatase and hydroxylases, are significantly asso-
ciated with both receptor levels and response to estrogen in target cancer tissues and
cells.12−15
In our own studies we have adopted an original intact cell analysis (see following
section) to investigate rates and patterns of estrogen metabolism in a panel of estab-
lished human cancer cell lines, either hormone responsive (e.g., MCF7, ZR75-1,
T47D) or unresponsive (e.g., MDA-MB-231, BT20, HBL100), from the human
breast. In particular, using this approach, we were able to assess formation and deg-
radation of various hydroxy estrogens, especially catechol estrogens (CCEs) and
their methoxy (MeO) derivatives. The major metabolic pathways eventually leading
to formation of estrogens and their hydroxy or methoxy derivatives are portrayed in
FIGURE 6. FIGURE 7 illustrates a typical chromatographic profile of estrogen metab-
olism in MCF7 human breast cancer cells.
In vitro data obtained in our laboratories clearly indicate that ER-positive breast
tumor cells privilege reductive pathways of estrogen metabolism leading to E2 ac-
cumulation, exactly as it occurs in vivo in ER-positive tumor tissues. On the other
hand, ER-negative cells preferentially oxidize E2 to E1, which is not further metab-
olized, and (as in ER-negative cancer tissues) accumulates as such. These results are
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FIGURE 6. Flow chart of major metabolic pathways that control formation of estro-
gens and their hydroxy and methoxy derivatives.
FIGURE 7. A typical HPLC profile of estrogen metabolism in MCF7 breast cancer
cells incubated for 72 h with tritiated estradiol. White and black peaks indicate free (F) and
sulfate (S) estrogens, respectively. Percent conversion rates for individual peaks were: (1)
E3: F, 1.03%; S, 1.10%. (2) E2: F, 36.46%; S, 31.44%. (3) 4MeOE2: F, 1.19%; S, 5.00%.
(4) 2MeOE2: F, ND; S, 3.70%. (5) E1: F, 16.69%; S, 2.26%. (6) 4MeOE1: F, 0.21%; S,
0.42%. (7) 2MeOE1: F, ND; S, 0.09%. ND, not detectable.
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largely at variance with those obtained using a crude-extract approach, in both quan-
titative and qualitative terms. In fact, while the overall 17βHSD activity, as measured
by intact cell analysis, is markedly lower than that expected on the basis of classical
enzymology, the extent of the oxidative component of 17βHSD diverges drastically
using the two different approaches, being significantly greater in ER-negative mam-
mary cancer cells or in ER-positive breast tumor tissues, respectively (data not
shown).
In hormone-responsive cells, including MCF7 and ZR75-1, we observed an early
production of either free or conjugated CCE after a 24-h incubation with a tritiated
estrogen precursor, either E2 or E1. In particular, appreciable amounts of free
2OHE2, 2MeOE1, and 2MeOE2, as well as of conjugate 2MeOE2, were consistently
detected in both cell lines, leading to nearly 5% formation of both hydroxy and meth-
oxy estrogens in MCF7 cells and 2.3% in ZR75-1 cells (TABLE 2). After 72-h incu-
bation, however, hydroxy estrogen production increased considerably, revealing the
formation of almost all major CCE and methoxy compounds (including 2OHE2,
2MeOE1, 2MeOE2, and 4MeOE1). 4MeOE2 was the prevalent metabolite among
either free or conjugate estrogens (not shown). From these experiments, there is also
consistent evidence that products of 4-hydroxylation (including both hydroxy and
methoxy compounds) are predominant over those of 2-hydroxylation, eventually
causing the ratio of 4-hydroxy estrogens to 2-hydroxy estrogens to be relatively high
in these cell model systems (TABLE 3). In addition, formation of CCE and methoxy
derivatives from E2 is in MCF7 cells twofold greater than that observed using E1 as
precursor (TABLE 3). This evidence may also be explained on the basis of a preva-
lently reductive activity of the 17βHSD enzyme in MCF7 cells, leading to accumu-
TABLE 2. Formation rates of hydroxy and methoxy estrogens in MCF-7 and ZR75-1
human breast cancer cells
Cell 2OH+2MeO 4OH+4MeO 4/2 Ratio
MCF-7 2.30  ±  0.09 2.12 ± 0.05 0.92 ± 0.02
ZR75-1 2.09 ± 0.10 0.20 ± 0.01 0.10 ± 0.01
NOTE: Cells were incubated for 24 hours with tritiated E2 as precursor. Values represent mean
±  SD of sum of free and conjugate metabolites of E2 from three separate experiments.
TABLE 3. Catechol- and methoxyestrogen formation in MCF7 cells after 72-h
incubation with estradiol (E2) or estrone (E1) as precursor
Tritiated precursor
3H-E2 3H-E1
2OH+2MeO 1.49 ± 0.09 0.70 ± 0.05
4OH+4MeO 2.66 ± 0.21 1.14 ± 0.07
4/2 ratio 1.78 ± 0.08 1.63 ± 0.08
NOTE: Values represent mean pmoles ± SD of sum of free and conjugate metabolites from
three separate experiments.
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lation of E2 and its hydroxy derivatives. Conversely, in ZR75-1 cells, where the
reductive 17βHSD activity is lower, the overall CCE formation rates are reduced and
ratios of 2-hydroxy to 4-hydroxy derivatives are changed (not shown).
The early formation of CCE in both MCF7 and ZR75-1 cells indicates that estro-
gen hydroxylation may represent an important metabolic pathway, while the preva-
lence of 4-hydroxy derivatives over 2-hydroxy derivatives is in accordance with our
in vivo data on intratissue estrogens.8 In separate experiments we have also inspected
estrogen formation in human breast cancer cells using tritiated androstenedione (Ad)
as an androgen precursor to assess the extent of aromatase activity on Ad, which rep-
resent a major source of estrogen production in postmenopausal women. Results
from these studies clearly reveal a consistent CCE production after 24- and 72-h in-
cubations (up to nearly 10% by 72 hours), with 4OHE2 and 2OHE1 being the two
most prevalent hydroxyestrogens (TABLE 4). 
INTACT CELL ANALYSIS
Different methodological procedures have been used to measure key enzyme ac-
tivities of sex steroid metabolism, either in vivo or in vitro. Unfortunately, results
from these studies diverge substantially. First, there is a lack of correlation between
tissue levels of endogenous hormones and both extent and direction of steroid me-
tabolism, as measured by the classical enzymology approach. It should be pointed
out that while some earlier studies used conditions that approximate the in vivo state
(fresh tissue slices unsupplemented with pyridine-nucleotide cofactors), the majori-
ty measured enzyme activities in more artificial environments (tissue homogenates
supplemented with NADPH as cofactor), which overlook the regulatory mechanisms
existing in intact cells and neglect the endogenous cofactors.
It should be emphasized that, from a methodological standpoint, measurement of
an enzyme system, a complex and dynamic structure, using crude cell and/or tissue
extracts and classical enzymology methods is doubtless far more artificial and puz-
zling than the quantitation of individual steroids in tumor tissue homogenates. Quan-
titative estimates of the enzyme kinetic data (Km and Vmax) are currently carried out
under artificial conditions (cell lysates, pH, temperature, excess of substrate concen-
tration, cofactor addition, and so forth) and optimized to yield the maximum conver-
sion rates for quantitation of a single enzyme activity. This condition largely differs
from physiological environment of pH, temperature, cofactor, substrate concentra-
tion, and enzyme inhibitors in vivo. Hence, classical enzymology data are highly un-
likely to be representative of the in vivo condition.
TABLE 4. Hydroxyestrogen formation in MCF-7 after 24-h and 72-h incubation with
androstenedione as precursor
Hours 4OHE2 2OHE1
24 0.93 ± 0.08 0.41  ±  0.03
72 3.92  ± 0.10 0.69  ±  0.06
NOTE: Values represent mean pmoles ± SD from three different experiments.
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TABLE  5. Major advantages of intact cell analysis and disadvantages of the classical
enzymology approach to measuring the activity of key steroid enzymes
Advantages of intact cell analysis
Simultaneous inspection of multiple enzyme activities in living, cultured cells using
physiological amounts of a steroid precursor
Assessment of rates and direction of steroid metabolism by continuous monitoring
of both precursor degradation and product formation, avoiding artificial variation
of cellular microenvironment
Disadvantages of classical enzymology
Disregards the regulatory mechanism existing in intact cells and neglects the endog-
enous cofactors
Quantitatively estimates enzyme kinetic data (Km and Vmax) under conditions opti-
mized to yield maximum conversion rates with artificial pH, temperature, cofac-
tor, and substrate concentration
No appraisal of the extent and direction of steroid metabolism
No correlation with intratissue amounts of endogenous steroids
TABLE 6. Efficiency values of radiometric detection of tritiated estradiol at
continuous flow in standard conditions
NOTE: dpm, decline/minute; cpm, count/minute.
dpm (theoretical) cpm (observed) Efficiency (%)
294 52 18
587 81 14
1174 192 16
2349 433 18
4699 987 21
9318 1524 16
18,798 3097 16
37,593 6125 16
75,187 13,463 18
TABLE  7. Detection limits and efficiency values of radiometric detection online to
RP-HPLC
aCounts per minute.
bPicomoles.
cValues represent mean  ± SD of six different analyses; processing cell culture medium spiked
with pure radiolabeled compounds.
dFemtomoles.
Compound
Detection limits
Moles cpma Efficiency (%)
[4-14C]E1 1.1b 70.2  ± 4.1c 56.2  ± 5.2c
[6,7-3H]E2 2.4d 51.3 ± 2.1c 17.3  ±  1.2c
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Aiming to assess rates and pathways of sex steroid metabolism, either in vivo or
in vitro, we originally developed, established, and optimized a novel approach we
named intact cell analysis.4,16 In this method, the use of reverse-phase high perfor-
mance liquid chromatography (RP-HPLC) with online radioactive detection allows
a simultaneous and sequential estimation of several enzyme activities in intact cul-
tured cells or tissue fragments incubated for variable time lengths (from a few min-
utes up to several days) with physiological amounts of a radioactive (tritiated) sex
steroid used as precursor. Using this approach, we could analyze, under strictly con-
trolled experimental conditions, the rates and direction of steroid conversion to a
wide range of either conjugate or unconjugated metabolites (up to 25) in a relatively
short time of analysis (20–30 minutes). This “live analysis” system permits contin-
uous monitoring and quantitation of both precursor degradation and formation of
several metabolic products; it avoids the artifacts of classically measured enzyme re-
actions and, notably, obtains more refined information on the metabolic direction in
individual tissues and cells. The advantages of this methodology, as opposed to the
disadvantages of classical enzymology approach, are summarized in TABLE 5.
It is noteworthy that radiometric detection online to HPLC is featured by high ef-
ficiency values (TABLE 6) and low detection limits (TABLE 7). This, combined with
the good linearity of this approach (FIG. 8), permits detection limits as low as 2.4
fmoles and 1.1 pmoles for pure tritiated E2 and pure carbonated E1, respectively
(TABLE 8). In addition, the use of the aluminum oxide acid (alumina) absorption ex-
traction method markedly improved recovery values of CCEs, hence further increas-
ing the sensitivity of this procedure. This represents an essential prerequisite to our
approach for studying metabolic pathways of gonadal steroids, either in vivo or in
vitro, where target tissues or cells are exposed to physiological concentrations of a
labeled precursor.
FIGURE 8. Linearity of radiometric detection online to RP-HPLC for 3H-E2. Regres-
sion equation: y = 1.824 + 0.968x. Correlation coefficient = 0.994. P < 10−6, Pearson’s test.
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It might be argued that intact cell analysis cannot be considered entirely represen-
tative of tissue dynamics in vivo. Intact cell analysis does, however, more closely ap-
proach the in vivo state than the artificial requirements of classical enzymology
procedures. Of course, one should place very wide confidence intervals in extrapo-
lating data obtained in vitro to the in vivo situation. In particular, the absence of the
stromal compartment should be carefully considered. However, some evidence
seems to corroborate results gained on cultured epithelial cancer cells. Preliminary
data obtained in our laboratories on primary cultures of stromal cells isolated from
primary breast tumor tissues appears to indicate that the stromal contribution to the
overall rates and direction of estrogen metabolism is relatively trivial (Castagnetta
and colleagues, in preparation). This would imply that the metabolic fate of circulat-
ing estrogens is mostly subjected to the metabolic behavior of tumor epithelial cells
and that expression and activity of key steroid enzymes in individual tissues and cells
may lead to local accumulation of more-or-less biologically active metabolites.
CONCLUSIONS
Fifteen years ago, on the occasion of an international meeting we held in Taorm-
ina (Sicily), we first introduced a new concept in the endocrinology of human ma-
lignancies—the peripheral formation, degradation, and action of sex steroids, which
suggested that hormonal regulation of target cancer cells may be directed primarily
by the local expression and activity of key enzymes in steroid metabolism.17 This
concept was further elaborated by Fernand Labrie, who coined the term intracrinol-
ogy to define hormone effects whereby both the ligand and its receptor interact with-
in the target cell.18
The evidence we present here suggests that estrogens may be implicated as initi-
ators, not just as promoters, in the carcinogenic process (see the paper by Cavalieri
and Rogan, this volume). In particular, our finding that the so-called minor estro-
gens, including CCE, other hydroxyestrogens (16αOHE1), and methoxy derivatives,
represent the majority of either urinary or intratumor estrogens in human breast can-
cer patients, whereas they are relatively scarce the in urine or mammary glands of
healthy women is strongly suggestive of the implication of these estrogen metabo-
lites in the initiation and/or promotion steps of breast carcinogenesis. Furthermore,
our data corroborate the results obtained by studies by Joachim Liehr,19 Ercole Cav-
alieri,20 and H. Leon Bradlow21 revealing that 4OHE2 and/or 16αOHE1 are elevated
in breast tumors as compared to normal mammary tissues, hence implying their role
as mutagens.
TABLE 8. Recovery values for selected catecholestrogens using the alumina
adsorption extraction method
Compound Recovery (%)
2OHE1 65−75
E1 65−72
2MeOE1 84−93
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Overall, the data presented in this volume, including our own, combined with
those accumulating in the literature, provide convincing evidence of the competence
of estrogens as complete carcinogens (both initiators and promoters) in the human
breast. Yet our recent studies on intratumor estrogens and the survival of breast can-
cer patients indicate that the potential role of individual estrogens in the onset and
the clinical progression of breast cancer should be kept separate, because distinct
estrogen derivatives may have diverse, if not opposite, roles in carcinogenesis and
the progression of this malignancy. There is now substantial indication that estro-
gens can be implicated in the initiation, promotion, and progression of human breast
cancer.
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